Kazuhiko Higashioka, M.D., Ph.D.
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Pericarditis | 1 | 2022 | 135 | 0.720 |
Why?
|
Pericardial Effusion | 1 | 2022 | 247 | 0.680 |
Why?
|
Interleukins | 2 | 2021 | 785 | 0.650 |
Why?
|
B-Lymphocyte Subsets | 4 | 2021 | 241 | 0.630 |
Why?
|
Scleroderma, Systemic | 1 | 2022 | 344 | 0.600 |
Why?
|
Mycophenolic Acid | 2 | 2022 | 343 | 0.600 |
Why?
|
Lupus Vasculitis, Central Nervous System | 2 | 2021 | 32 | 0.560 |
Why?
|
Mycobacterium bovis | 1 | 2015 | 147 | 0.480 |
Why?
|
Pneumonia, Pneumocystis | 1 | 2016 | 245 | 0.470 |
Why?
|
Azathioprine | 1 | 2015 | 356 | 0.450 |
Why?
|
Hyperkalemia | 1 | 2016 | 231 | 0.450 |
Why?
|
Granuloma | 1 | 2015 | 327 | 0.430 |
Why?
|
Urologic Neoplasms | 1 | 2015 | 320 | 0.380 |
Why?
|
Arthritis, Rheumatoid | 3 | 2021 | 3763 | 0.360 |
Why?
|
Renal Insufficiency | 1 | 2016 | 820 | 0.340 |
Why?
|
Carcinoma in Situ | 1 | 2015 | 796 | 0.330 |
Why?
|
Antigens, Differentiation, T-Lymphocyte | 2 | 2021 | 899 | 0.330 |
Why?
|
Angiotensin-Converting Enzyme Inhibitors | 1 | 2016 | 1523 | 0.320 |
Why?
|
Immunoglobulin G | 1 | 2020 | 4541 | 0.300 |
Why?
|
CD8-Positive T-Lymphocytes | 1 | 2021 | 4550 | 0.290 |
Why?
|
Th1 Cells | 2 | 2020 | 1032 | 0.250 |
Why?
|
Interleukin-6 | 1 | 2015 | 3215 | 0.250 |
Why?
|
Lupus Erythematosus, Systemic | 3 | 2022 | 2159 | 0.240 |
Why?
|
Kidney Diseases | 1 | 2015 | 2093 | 0.230 |
Why?
|
Chemokine CXCL10 | 2 | 2021 | 316 | 0.210 |
Why?
|
Immunosuppressive Agents | 1 | 2015 | 4166 | 0.210 |
Why?
|
Urinary Bladder Neoplasms | 1 | 2015 | 2276 | 0.200 |
Why?
|
Immunologic Memory | 2 | 2021 | 1354 | 0.200 |
Why?
|
Prednisolone | 1 | 2022 | 327 | 0.190 |
Why?
|
Behcet Syndrome | 1 | 2021 | 86 | 0.180 |
Why?
|
Proto-Oncogene Proteins c-bcl-6 | 1 | 2020 | 191 | 0.170 |
Why?
|
Lymphocyte Count | 1 | 2021 | 780 | 0.160 |
Why?
|
Kidney Neoplasms | 1 | 2015 | 4312 | 0.160 |
Why?
|
CD4-Positive T-Lymphocytes | 2 | 2021 | 4353 | 0.150 |
Why?
|
Anti-Bacterial Agents | 1 | 2016 | 7408 | 0.140 |
Why?
|
Administration, Intravesical | 1 | 2015 | 92 | 0.130 |
Why?
|
Leukemia-Lymphoma, Adult T-Cell | 1 | 2016 | 164 | 0.130 |
Why?
|
Interleukin-10 | 1 | 2020 | 1175 | 0.120 |
Why?
|
Ascites | 1 | 2016 | 338 | 0.120 |
Why?
|
RANK Ligand | 1 | 2016 | 318 | 0.120 |
Why?
|
Disease Susceptibility | 1 | 2021 | 1791 | 0.110 |
Why?
|
Cell Communication | 1 | 2021 | 1653 | 0.110 |
Why?
|
Lymphocyte Activation | 2 | 2021 | 5496 | 0.110 |
Why?
|
T-Lymphocyte Subsets | 1 | 2021 | 1810 | 0.100 |
Why?
|
Antirheumatic Agents | 1 | 2021 | 1374 | 0.100 |
Why?
|
Hypertension, Pulmonary | 1 | 2022 | 1570 | 0.090 |
Why?
|
Antibodies, Antinuclear | 2 | 2021 | 344 | 0.090 |
Why?
|
Ischemic Attack, Transient | 1 | 2015 | 901 | 0.090 |
Why?
|
Cytokines | 2 | 2021 | 7343 | 0.080 |
Why?
|
Aged | 7 | 2022 | 169152 | 0.080 |
Why?
|
B-Lymphocytes | 1 | 2020 | 4742 | 0.070 |
Why?
|
Dementia | 1 | 2021 | 2649 | 0.070 |
Why?
|
Female | 11 | 2022 | 391270 | 0.060 |
Why?
|
Cells, Cultured | 1 | 2020 | 18957 | 0.060 |
Why?
|
Humans | 13 | 2022 | 760621 | 0.060 |
Why?
|
Iloprost | 1 | 2022 | 25 | 0.050 |
Why?
|
Epoprostenol | 1 | 2022 | 248 | 0.050 |
Why?
|
Chemokine CXCL9 | 1 | 2020 | 135 | 0.050 |
Why?
|
Acetamides | 1 | 2022 | 256 | 0.040 |
Why?
|
Male | 7 | 2021 | 359744 | 0.040 |
Why?
|
Solubility | 1 | 2021 | 1088 | 0.040 |
Why?
|
Lupus Nephritis | 1 | 2021 | 318 | 0.040 |
Why?
|
Pyrazines | 1 | 2022 | 1199 | 0.030 |
Why?
|
Middle Aged | 6 | 2021 | 220352 | 0.030 |
Why?
|
Adult | 6 | 2022 | 219994 | 0.030 |
Why?
|
Enzyme-Linked Immunosorbent Assay | 1 | 2021 | 3804 | 0.030 |
Why?
|
Severity of Illness Index | 2 | 2021 | 15840 | 0.030 |
Why?
|
Autoimmunity | 1 | 2021 | 1370 | 0.030 |
Why?
|
Interferon-gamma | 1 | 2020 | 3157 | 0.030 |
Why?
|
Osteoclasts | 1 | 2016 | 711 | 0.030 |
Why?
|
Coculture Techniques | 1 | 2016 | 1342 | 0.020 |
Why?
|
Cell Separation | 1 | 2016 | 1720 | 0.020 |
Why?
|
Risk Factors | 1 | 2016 | 74359 | 0.020 |
Why?
|
Treatment Outcome | 1 | 2015 | 65017 | 0.020 |
Why?
|
Gene Expression | 1 | 2020 | 7588 | 0.020 |
Why?
|
Retrospective Studies | 1 | 2016 | 80372 | 0.020 |
Why?
|
Case-Control Studies | 1 | 2021 | 22053 | 0.010 |
Why?
|
Aged, 80 and over | 2 | 2020 | 58995 | 0.010 |
Why?
|
Quality of Life | 1 | 2022 | 13308 | 0.010 |
Why?
|
Prognosis | 1 | 2021 | 29658 | 0.010 |
Why?
|
Cell Differentiation | 1 | 2016 | 11481 | 0.010 |
Why?
|
Young Adult | 1 | 2016 | 58741 | 0.010 |
Why?
|